Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Macular Edema With Central Retinal Vein Occlusions”

Showing 5 of 0 results

Large-scale testing (Phase 3)Study completedNCT01535261
What this trial is testing

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Who this might be right for
Macular EdemaCentral Retinal Vein Occlusion
Novartis Pharmaceuticals 357
Testing effectiveness (Phase 2)Study completedNCT01724554
What this trial is testing

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

Who this might be right for
Central Retinal Vein OcclusionProliferative Diabetic Retinopathy
Ophthalmic Consultants of Boston 24
Testing effectiveness (Phase 2)Study completedNCT00088283
What this trial is testing

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Who this might be right for
Retinal Vein Occlusion
Eyetech Pharmaceuticals 90
Large-scale testing (Phase 3)Study completedNCT05850520
What this trial is testing

Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

Who this might be right for
Macular Edema Secondary to Retinal Vein Occlusion
Bayer 892
Testing effectiveness (Phase 2)Study completedNCT04667910
What this trial is testing

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Who this might be right for
Central Retinal Vein Occlusion
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 60

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation